^
Association details:
| Biomarker: | MYD88 L265P |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Xolremdi (mavorixafor) (CXCR4 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA WITH MYD88 AND CXCR4 MUTATIONS
Published date:
05/12/2021
Excerpt:
This study examines the safety and efficacy of mavorixafor in combination with ibrutinib in patients with WM with MYD88 and CXCR4 mutations….Six out of 7 patients showed decrease in IgM after 1 cycle. Four patients were treated for ≥3 cycles; all had decrease in serum IgM, with 2 achieving a ≥50% decrease from baseline consistent with partial response after 3 cycles (median decrease, 51.0%; range, 4.4%–84.5%).
Trial ID:
